Status:
UNKNOWN
Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)
Lead Sponsor:
Huashan Hospital
Conditions:
Mild Cognitive Impairment
Eligibility:
All Genders
50-80 years
Phase:
NA
Brief Summary
Patients of vascular cognitive impairment-no dementia (VCIND) in one group is prescribed cilostazol,in the other group is prescribed aspirin. Evaluate both of them in cognitive function, MRI and other...
Eligibility Criteria
Inclusion
- Aged between 50-80, both gender；
- Small vessel disease and associated cognitive impairment, diagnosed as VCIND；
- Non-specific subjective symptoms (dizziness, somnolence, numbness in limbs) are acceptable.
- Normal hepatic and renal function.
- With good compliance.
Exclusion
- Aged above 80 or less than 50.
- Dementia.
- Cerebral infarction(\>2cm).
- Major vascular lesion. (stenosis\>50%).
- Cardiac cerebral infarction.
- Intracerebral Hemorrhage.
- Clinical manifestations cannot attribute to small vessel disease.
- Major depression or dysfunction in speech, visual ability, hearing or aphasia that would interfere with the cognitive assessment.
- Severe systematic organic impairment(cardiac, hepatic, renal dysfunction).
- Thrombocytopenic Purpura.
- History of hemorrhage in digestive system or surgery in past 3 months.
- Previously on cilostazol treatment for more than 3 month.
- Allergic to aspirin or cilostazol.
- Enrolled in other clinical trials in past 3 months.
- Lack of informed consent or compliance.
- Contraindications for MRI scan.
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2015
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01872858
Start Date
November 1 2010
End Date
November 1 2015
Last Update
June 7 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Neurology, Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200040